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The aim of our study was to investigate the metastatic
pathways of melanoma cells in sentinel and other
regional lymph nodes. The term ‘‘sentinel lymph
node’’ means that the first lymph node of the draining
site of a primary tumor is never bypassed in malignant
melanoma. In this case lymph node dissection would
be necessary only when melanoma cells are detected
in the sentinel node. Tyrosinase reverse transcriptase–
polymerase chain reaction was applied to search for
metastatic melanoma in the sentinel lymph node and
in further lymph nodes of a complete lymph node basin
in patients who underwent lymph node dissection. In
24 patients with malignant melanoma the draining site
of the tumor was marked by lymphoscintigraphy and
by intraoperative injection of patent blue V in the area
around the primary tumor. The lymph nodes of the
affected basin were excised and prepared for histopa-
thologic, immunohistochemical, and molecular bio-
logic examinations. Regarding the sentinel lymph
node, 10 of 24 patients showed morphologic evidence
Melanoma accounts for 1–3% of all malignanttumors (Brossart et al, 1993). The dramaticincrease of the incidence of malignant melanomain Europe, Australia, and the U.S.A. duringthe last decades has been mainly attributed to
exposure to high ultraviolet doses (Sober et al, 1991). Although
today melanoma is diagnosed more frequently in early stages of
disease and therefore shows a better overall survival (Sober et al,
1991), once tumor cells can be detected in the regional lymph
node (LN), the patients have a poorer prognosis. For example, in
patients with clinical and pathologic stage I disease (Breslow
thickness below 1.50 mm, Clark level III and without involvement
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for metastases, three additional patients showed only
tyrosinase transcripts. In 11 of these 13 cases we
found one or more nonsentinel lymph nodes with
morphologically detectable melanoma cells and/or
tyrosinase mRNA. Interestingly, in seven of 24 patients
a positive tyrosinase reverse transcriptase–polymerase
chain reaction was received in nonsentinel lymph
nodes, whereas the sentinel lymph node was negative,
not only for all histologic examinations but also by
tyrosinase reverse transcriptase–polymerase chain
reaction. In five of seven patients of the latter group,
gp100 reverse transcriptase–polymerase chain reaction
was carried out, showing also gp100 mRNA in nonsen-
tinel lymph nodes only. Our data indicate that the
concept of the sentinel lymph node may miss micro-
metastases. Whether such micrometastases cause a
recurrence or a metastasis of malignant melanoma, or
can be destroyed by the immune system, remains to
be clarified. Key words: lymph node dissection/lymph node
mapping/melanoma cells/reverse transcriptase-PCR. J Invest
Dermatol 113:554–559, 1999
of regional LN) a 5 y survival rate between 80% and 100% was
reported, depending on tumor thickness (Slominski et al, 1995).
Prognosis rapidly decreases to a 5 y survival rate of 20–30% in
patients with LN metastases (Koh et al, 1986). Therefore, the
excision of the tumor and LN dissection represent an effective
therapy in malignant melanoma, despite an ongoing discussion
about the value of elective LN dissection in patients with clinically
unsuspicious LN and medium- or high-risk melanoma.
The technique of sentinel LN (SLN) mapping and selective
lymphadenectomy has been introduced to optimize melanoma
treatment (Wong et al, 1991; Morton et al, 1992; Lingam et al,
1994). It is based on the concept that melanoma cells via the
lymphatics regularly enter the first regional LN (SLN). If the SLN
would reflect the metastatic status of the entire LN area, only
patients with melanoma cell positive SLN should be subjected to
elective LN dissection. In patients with negative SLN local excision
of the primary tumor would be an appropriate therapy (Ross et al,
1993; Reintgen et al, 1994; Glass et al, 1995; Godellas et al, 1995).
Recently, there have been attempts to detect small numbers of
melanoma cells by the polymerase chain reaction (PCR) technique.
Smith et al (1991) were the first to describe a reverse transcription
(RT–PCR) for tyrosinase mRNA to detect melanoma cells in
peripheral blood. Others modified this technique to detect micro-
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Table I. Survey on the patients investigated
Pat. no. Age Sex Melanoma type Thickness Clark level Site affected LN basin affected Dissected LN Clinical stage TNM
n
1 67 m SSM 3,06 IV trunk axilla 7 III pT4,N0,Mx
2 52 f SSM 1,4 IV trunk axilla 7 II pT3,N0,Mx
3 60 f ALM 2,34 IV leg groin 10 III pT2,N1,Mx
4 55 f NM 1,59 IV leg groin 12 III pT3,N1,Mx
5 62 f SSM 1,45 IV trunk axilla 6 I pT3,N0,Mx
6 68 m NM 1,62 III arm axilla 8 I pT2,N0,Mx
7 60 m SSM 1,94 III trunk axilla 8 I pT2,N0,Mx
8 61 m SSM 4,2 IV trunk axilla 12 II pT3,N0,Mx
9 44 f NM 1,85 IV trunk axilla 10 II pT3,N0,Mx
10 34 m SSM 1,27 IV arm axilla 7 III pT3,N1,Mx
11 46 f SSM 2,37 IV trunk axilla 12 II pT3,N0,Mx
12 60 m NM 3,0 IV trunk axilla 8 II pT3,N0,Mx
13 46 m SSM 2,31 IV trunk axilla 9 III pT3,N1,Mx
14 58 m #a 9 IV hand axilla 8 III pT4a,N1,Mx
15 61 f SSM 1,9 IV leg axilla 6 III pT3,N1,Mx
16 54 f NM 2,7 IV leg groin 19 III pT3,N1,Mx
17 64 f #a 1,19 IV leg groin 20 III pT3,N1,Mx
18 45 m NM 10 IV leg groin 18 III pT4a,N1,Mx
19 68 m SSM 1,53 III leg groin 14 III pT3,N1,Mx
20 65 m NM 2,07 IV leg groin 7 III pT3,N1,Mx
21 63 f NM 4,0 IV buttock groin 22 II pT3,N0,Mx
22 45 m SSM 0,72 III chest axilla 10 I pT2,N0,Mx
23 63 m NM 4,3 IV chest axilla 12 II pT3,N0,Mx
24 71 f SSM 2,8 IV arm axilla 12 II pT3,N0,Mx
aNo classification possible.
metastases also in LN (Wang et al, 1994; Schwu¨rzer-Voit et al,
1996; Blaheta et al, 1998). It was demonstrated, that LN from
patients with tumors other than melanoma do not express RT–PCR
detectable tyrosinase mRNA (Blaheta et al, 1998). As tyrosinase
expression is restricted to melanocytes, melanocytic nevus cells
(nevocytes), and in melanoma cells, the detection of tyrosinase
mRNA indicates the presence of melanoma cells in the LN
investigated (Foss et al, 1995). Nodal nevocytes causing a positive
tyrosinase RT–PCR, however, were found in dissected LN from
melanoma patients (Carson et al, 1996). Thus, a careful interpreta-
tion of positive tyrosinase RT–PCR results in patients with a
melanoma-negative histopathology is strongly recommended. In
our study, the SLN as well as the other LN of a given LN basin
from 24 melanoma patients were investigated following mapping
by histopathology, immunohistochemistry, and tyrosinase RT–PCR
in order to detect the presence of LN metastasis or micrometastasis.
MATERIALS AND METHODS
Biopsy material The entire regional LN from 24 patients with malignant
melanoma in clinical stages I–III (classification of the American Joint
Committee on Cancer) were examined. Informed consent was obtained.
The patients were recruited from the Department of Dermatology, Charite´
University Hospital and had complete physical and medical histories.
Tumor thickness and level of invasion were documented as well as tumor
type and stage of disease according to the TNM classification of the
International Union Against Cancer (UICC, Hermanek et al, 1989). In
eight patients with malignant melanoma of the leg, LN were excised from
the inguinal and iliacal region. In the other cases the axillary LN basin was
affected: 12 patients had malignant melanoma of the trunk or shoulder and
four patients had malignant melanoma of the arm or thumb. All clinical
and histologic characteristics are summarized in Table I.
Lymphography and LN mapping By combination of lymphoscinti-
graphy and patent blue injection the SLN was detected in all patients.
Lymphoscintigraphy was performed 24 h before elective LN dissection by
intracutaneous injection of Tc99m-Nano colloid in four to six aliquots
around the primary tumor or the site of previous excision. Imaging was
performed using a gamma camera, and the lymphatic drainage was marked
on the skin. Similarly, patent blue V was injected directly before surgery
to visualize the afferent lymphatics and the SLN. First, the SLN was
excised. All following non-SLN of the draining basin were sectioned en
bloc together with the surrounding fatty tissue. LN mapping was performed
systematically node by node, beginning at the site of the tumor and SLN.
The LN were numbered in sequence as found. Between six and 22 LN
per basin (mean value 11) were excised. In total, 264 LN were examined.
After being sliced the nodes were inspected macroscopically to detect
structures suspicious of metastatic malignant melanoma, e.g., discolored or
hemorrhagic tissue. One part was snap-frozen in liquid nitrogen for
molecular biologic analyses. The other parts were prepared for hematoxylin
and eosin staining and immunohistochemical staining for HMB-45 protein.
Six LN of five patients with a cutaneous T cell lymphoma, without any
signs or history of melanoma, were included as negative controls for the
tyrosinase and gp100 RT–PCR (see below).
RNA extraction Fifty to 250 mg of the frozen LN specimens were lyzed
with heated lysis buffer (QIAGEN, Hilolen, Germany) and immediately
homogenized with a rotor-stator homogenizer. The subsequent extraction
of the total RNA by the Oligotex Direct mRNA Kit (QIAGEN) was
performed as described by the manufacturer.
cDNA synthesis Reverse transcription was carried out with SuperScript
Preamplification System (Gibco BRL, Eggenstein, Germany) directly
following RNA extraction as recommended by the manufacturer. All
RNA extraction and reverse transcription procedures were performed
under sterile conditions with autoclaved tubes and pipettes.
PCR To avoid contamination components of the PCR were handled
under a laminar air flow hood in a separate room. The PCR assays were
performed in a programmable thermocycler (Landgraf, Langenhagen,
Germany) as previously described with some modifications immediately
following the cDNA synthesis. Primers for human tyrosinase were used as
published (Smith et al, 1991; Ponnazhagan et al, 1994). The outer primers
HTYR 1 and 2 produce a PCR fragment of 284 bp. The inner primers
HTYR 3 and 4 produce a PCR fragment of 207 bp. The reaction mix
consisted of 51.5 µl sterile water, 7.5 µl 10 3 PCR buffer (Perkin Elmer,
Weiterstadt, Germany), 7.5 µl MgCl2 (25 mM, Perkin Elmer), 3.0 µl
dNTP (10 mM each, Pharmacia Biotech, Freiburg, Germany), 0.4 µl
AmpliTaq Polymerase (5 U per µl, Perkin Elmer), 1.5 µl (20 pmol) of
each primer, and 3 µl of cDNA. PCR conditions were set up as follows:
95°C for 5 min, 30 cycles of 60°C for 90 s, 72°C for 90 s, and 94°C for
90 s. For re-amplification with inner primers, 3 µl of a 1 in 50 dilution
of the PCR products were processed as described above. PCR products,
i.e., 8 µl of each reaction mixture were separated by electrophoresis on
ethidium bromide containing 2% agarose gels with HincII digests of φX
174 (USB) as DNA molecular weight marker (Fig 1). To control the
integrity of each mRNA sample a PCR with primers for the human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was set up as
published (Platzer et al, 1994). Samples without DNA were subjected to
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Figure 1. Tyrosinase and GAPDH RT–PCR products separated on
an ethidium bromide stained 2% agarose gel. cDNAs of patient 8
(see Table V), lane 1, SLN; lanes 2–7, LN 2–7; lane 8, empty; lane 9,
positive control (melanoma cell line); lane 10, negative control (no DNA);
M, size standard HincII digest of phi X174 DNA.
PCR as negative control. In order to exclude artifacts caused by contaminat-
ing genomic DNA, PCR was performed without prior reverse transcriptase
reaction. cDNA produced from the melanoma cell line MeWo was used
as positive control for the GAPDH and tyrosinase RT–PCR. For some
melanoma patients and the control LN, a RT–PCR for gp100 mRNA
was performed according to Spagnoli et al (1995). The conditions were as
follows: 94°C for 5 min, 40 cycles of 56°C for 60 s, 72°C for 120 s, and
94°C for 60 s. The PCR was regarded as positive if a 334 bp fragment was
generated. The melanoma cell line SK-Mel 29 served for positive control.
Sequencing of tyrosinase RT–PCR products The correctness of the
base sequence of the PCR-generated tyrosinase DNA fragments was
confirmed by direct DNA sequencing. The amplification products of three
different templates were purified from agarose gels (NuSieve, 3%, FMC
Bioproducts, Rockland, U.S.A.). The band of interest (207 bp DNA
fragment) obtained with primers HTYR 3 and 4 was cut out and the
DNA was recovered. The sequencing reaction was performed as dye
terminator cycle sequencing by means of the PRISM Ready Reaction
DyeDeoxy Terminator Cycle Sequencing Kit (Perkin Elmer). For each
reaction 50 ng DNA were used as template with 5 ng of the primers
HTYR 3 or 4, respectively. The sequencing reaction, the purification of
its products and the preparing of the samples were carried out following
the kit protocol. Finally, the samples were analyzed on the automated ABI
373A sequencer. For each sample the nucleotide residues 822–1019, i.e.,
a 196 bp segment of the corresponding 207 bp DNA fragment was found
correctly (not shown here).
RESULTS
Overall findings in 264 LN from 24 patients In 223 of 264
LN samples of the 24 melanoma patients (stages pT 2–4) mRNA
extraction and cDNA were successful as demonstrated by the
GAPDH RT–PCR. These 223 samples were subjected to tyrosinase
RT–PCR, and in selected samples also to gp100 RT–PCR.
All cDNA derived from the control specimen provided positive
GAPDH RT–PCR but negative tyrosinase and gp100 RT–PCR.
From all patients, the entire LN of the respective regional LN area
were investigated. Regarding all 24 patients, 10 cases (42%)
had histologic and/or immunohistologic evidence for melanoma
metastasis in the SLN, three patients (13%) showed mRNA
transcripts for tyrosinase without morphologic evidence for melan-
oma metastasis in the SLN, whereas four patients (17%) were
completely negative using these techniques. Seven patients (29%)
had tyrosinase mRNA in the non-SLN whereas the SLN was
negative by all methods applied.
A survey on the results of those 223 LN samples providing a
functional cDNA (22 SLN, 201 non-SLN) is shown in Table II:
The frequency of morphologic demonstration of melanoma meta-
stasis as well as tyrosinase mRNA was clearly higher in the SLN
as compared with the non-SLN, indicating the functional power
of SLN to capture and retain metastatic melanoma cells for some
time. From the 201 non-SLN with an intact RNA/cDNA, 15
Table II. Results of histologic, immunohistologic, and
tyrosinase RT–PCR in 22 SLN and 201 non-SLN samples
with a positive GAPDH signal
Positive samples by SLN Non-SLN
n % n %
Histology 1 immunohistology 1 RT2PCR 5 23 14 7
Histology 1 immunohistology 2 9 1 0.5
Immunohistology 1 RT2PCR 2 2 2 2
RT2PCR 3 14 41 20.5
Immunohistology 1 4 2 2
None of the applied methods 11 50 145 72
(7.5%) showed morphologic evidence for metastatic melanoma,
whereas 41 (20,5%) contained only tyrosinase transcripts. Regarding
the non-SLN, 145 of 201 specimen (72%) were completely
negative. It is important to realize that these figures for non-SLN
reflect the overall number of non-SLN but not percentages of the
patients investigated.
To assess these overall findings on a patient-based analysis, we
formed four groups: first, patients with morphologically affected
SLN; secondly, those with no morphologic evidence for melanoma
in the SLN but demonstration of tyrosinase transcripts; a third
group with completely negative findings in SLN but positive in at
least one non-SLN; and lastly, patients without any positive findings.
Patients with morphologically affected SLN As can be seen
from Table III, in this group of 10 patients six had further
morphologically affected non-SLN. The number of morpholo-
gically affected non-SLN varied from one (patients 4, 13, 16, 19)
to five (patients 3 and 15, both with Clark level IV melanomas).
Tyrosinase mRNA was detected in seven patients in this group.
Whereas in patient 19 the histologically positive non-SLN was
negative for tyrosinase mRNA despite positive GAPDH control,
patients 10 and 14 showed tyrosinase transcripts in three morpholo-
gically negative non-SLN. From the SLN of patients 14 and 17
no functional cDNA was received. Most morphologically positive
LN with an intact cDNA showed also tyrosinase transcripts (19 of
23, 83%).The number of reverse transcriptase-positive non-SLN
(27) exceeded that of morphologically positive non-SLN (14)
substantially.
Patients with morphologically negative but tyrosinase RT–
PCR positive SLN Patients 5, 9, and 11 expressed tyrosinase
mRNA in their SLN without morphologic evidence for melanoma
(Table IV). In all three cases, also non-SLN (one, eight, or seven,
respectively) contained tyrosinase transcripts.
Patients with morphologically and tyrosinase RT–PCR
negative SLN and positive non-SLN Seven of 24 patients
(29%) showed a positive tyrosinase RT–PCR in one or more non-
SLN, whereas the SLN was negative by all methods applied
(Table V). In this group, two tumors were low-risk melanomas
(Breslow thickness below 1.50 mm), the remaining five cases were
intermediate- and high-risk tumors. In four cases, only one of
the examined non-SLN was found to be positive for tyrosinase
transcripts. In patient 8, tyrosinase RT–PCR was positive in four
non-SLN (shown in Fig 1). In one case (patient 20) the tyrosinase
mRNA expression corresponded to morphologic detection of
metastatic melanoma. In all cases, where a RT–PCR for gp100
was performed, gp100 transcripts were also not found in the SLN
(Table V). We detected gp100 mRNA in tyrosinase mRNA-
positive non-SLN, however, with only one exception (patient 20).
In this patient the detection of gp100 mRNA failed, although the
tyrosinase mRNA containing non-SLN was also morphologically
positive. Particular clinical features distinguishing patient 20 from
the four patients which showed gp100 transcripts were not found
(see also Table I).
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Table III. Histologic, immunohistologic, and molecular
analysis of regional LN in patients with morphologically
positive SLNa
Patient 3, LN 1 2 3 4 5 6 7 8 9 10
Histopathology 1 1 1 1 2 2 1 2 2 1
Immunohistology 1 1 1 1 2 2 1 2 2 1
mRNA tyrosinase 1 1 1 1 # # 1 # 1 1
Patient 4, LN 1 2 3 4 5 6 7 8 9 10 11 12
Histopathology 1 2 2 2 1 2 2 2 2 2 2 2
Immunohistology 1 2 2 2 1 2 2 2 2 2 2 2
mRNA tyrosinase 1 2 1 2 1 2 2 2 1 2 2 2
Patient 10, LN 1 2 3 4 5 6 7
Histopathology 2 2 2 2 2 2 2
Immunohistology 1 2 2 2 2 2 2
mRNA tyrosinase 2 2 1 1 1 2 2
Patient 13, LN 1 2 3 4 5 6 7 8 9
Histopathology 1 2 2 2 1 2 2 2 2
Immunohistology 1 2 2 2 1 2 2 2 2
mRNA tyrosinase 1 1 2 1 1 1 1 2 1
Patient 14, LN 1 2 3 4 5 6 7 8
Histopathology 1 2 2 2 2 2 2 2
Immunohistology 1 2 2 2 2 2 2 2
mRNA tyrosinase # # # # # 1 1 1
Patient 15, LN 1 2 3 4 5 6
Histopathology 1 1 1 1 1 1
Immunohistology 1 1 1 1 1 1
mRNA tyrosinase 1 1 1 1 1 1
Patient 16, LN 1 2 3 4 5 6–18 19
Histopathology 1 2 2 2 2 2 1
Immunohistology 1 2 2 2 2 2 1
mRNA tyrosinase 1 2 2 2 # 2 1
Patient 17, LN 1 2 3 4 5–7 8 9 10–13 14 15 16–19 20
Histopathology 1 2 2 2 2 2 2 2 2 2 2 2
Immunohistology 1 2 2 2 2 2 2 2 2 2 2 2
mRNA tyrosinase # # 2 2 # 2 # 2 # 2 # 2
Patient 18, LN 1 227 8 9 10 11 12 13–16 17 18
Histopathology 1 2 2 2 2 2 2 2 2 2
Immunohistology 1 2 2 2 2 2 2 2 2 2
mRNA tyrosinase 2 2 # 2 # 2 # 2 # 2
Patient 19, LN 1 2 3 4 5 6 7 8 9 10 11–14
Histopathology 1 2 2 2 2 2 2 2 2 1 2
Immunohistology 1 2 2 2 2 2 2 2 2 1 2
mRNA tyrosinase 2 2 2 2 2 2 2 2 2 2 2
aLN1 5 SLN; #, not tested: negative GAPDH RT2PCR.
Table IV. Histologic, immunohistologic, and molecular
analysis of regional LN in patients with morphologically
negative and tyrosinase RT–PCR positive SLN
Patient 5, LN 1 2 3 4 5 6
Histopathology 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2
mRNA tyrosinase 1 2 1 2 2 2
Patient 9, LN 1 2 3 4 5 6 7 8 9 10
Histopathology 2 2 2 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2 2 2 2
mRNA tyrosinase 1 1 1 1 1 1 1 1 1 2
Patient 11, LN 1 2 3 4 5 6 7 8 9 10 11 12
Histopathology 2 2 2 2 2 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2 2 2 2 2 2
mRNA tyrosinase 1 1 2 1 1 2 1 1 1 # 1 #
LN1 5 SLN; #, not tested: negative GAPDH RT2PCR.
Additionally, also some of the tyrosinase RT–PCR negative
non-SLN contained gp100 mRNA. There was no association
between morphologic changes which usually can be found in
regional LN of malignant tumors, i.e., hyperplasie of lymph follicles,
histiocytosis of the marginal sinus or infiltration of the fibrotic
capsule with the presence of tyrosinase or gp100 mRNA in the
RT–PCR positive non-SLN.
DISCUSSION
The aim of our study was to investigate the metastatic pathways
of melanoma cells in regional LN. Detailed understanding of these
processes would be important in new surgical concepts such as that
of the SLN (Morton et al, 1992; Ross et al, 1993; Reintgen et al,
1994; Godellas et al, 1995). Because of the mainly lymphatic spread
of malignant melanoma, the SLN ideally would provide information
concerning the probability of metastatic involvement of other LN
in the LN basin and further systemic dissemination of melanoma
cells, respectively.
The first question to be discussed is that of specificity of the
techniques used. It is generally accepted, that in most instances
histopathologic and immunohistochemical assessment distinguish
between melanoma cells and other atypical cells in the LN,
particularly in patients with high-risk melanoma. In our study, the
melanoma cell detection in LN was performed using three tech-
niques of different sensitivities and specificities, i.e., histology,
immunohistochemistry, and RT–PCR for tyrosinase and gp100.
Concerning tyrosinase RT–PCR, some authors reported on false
positive results as a major technical problem either attributed to
carryover contamination (Foss et al, 1995) or to too high numbers
of amplification cycles in the PCR set up (Smith et al, 1991). With
appropriate controls we made sure to avoid these problems.
There are also doubts about the specificity of melanoma cell
detection in LN by tyrosinase RT–PCR. In melanoma patients, a
nodal frequency of nevus cell aggregates from 0.54 to 1.2% was
described (Bautista et al, 1994; Carson et al, 1996; Blaheta et al,
1998). These nodal nevi may imitate melanoma metastasis providing
also a positive outcome of tyrosinase RT–PCR. Although as much
as 3.9% of the investigated SLN showed nodal nevi, however, by
far fewer non-SLN, i.e., only 0.01% did so (Carson et al, 1996).
In all LN investigated in our study an experienced pathologist did
not find any melanocytic nevus cells by histology or immunohisto-
chemistry. Generally, we see such nevus cell aggregates in LN of
melanoma patients very rarely. Five of seven cases of our patient
group, assumed to have so-called ‘‘skip’’ metastases, were also tested
for gp100 mRNA presence. Overall, the data of the tyrosinase
RT–PCR were confirmed by the gp100 assay. In conclusion,
we assume that in the vast majority of LN samples melanoma
micrometastasis were indeed responsible for the positive tyrosinase
RT–PCR, also in the morphologically negative specimen. This is
in accordance with recent findings of Blaheta et al (1998), who
applied the same PCR technique. In repeated histopathologic
examinations they found in none of 87, morphologically negative
but tyrosinase mRNA positive LN nodal nevocytes. The authors
demonstrated a correlation between positivity in the tyrosinase
RT–PCR on one hand and Breslow’s tumor thickness on the
other. Thus, the probability that the positive tyrosinase RT–PCR
is caused by nodal nevi is low, particularly in morphologically
negative non-SLN.
In a few of LN we received a negative tyrosinase RT–PCR
despite of histopathologic and immunohistochemical evidence for
melanoma cells. Obviously, in these samples the negative tyrosinase
RT–PCR was a consequence of the LN preparation procedure:
immediately after excision, every LN was cut into two sections,
one used for RNA isolation, the other one for histologic staining.
In LN carrying low numbers of melanoma cells, these cells might
be restricted to one of the sections. This would explain the finding
of LN specimens with negative tyrosinase RT–PCR and positive
histopathology/immunohistochemistry as well as those with positive
RT–PCR but morphologically negative. The latter combination
occurred much more frequently, however, most likely due to the
substantially higher sensitivity of the RT–PCR.
Because the problem of investigating different LN sections for
histopathologic examinations and tyrosinase RT–PCR remains, we
would recommend the investigation of each SLN with serial
sections to improve the sensitivity of morphologic detection. Both,
serial sections and the technique of RT–PCR, however, are
hardly possible in the routine diagnostic procedures because of an
enormous expenditure and time demand.
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Table V. Histologic, immunohistologic, and molecular analysis of regional LN in patients with morphologically and
tyrosinase RT–PCR negative SLN but positive non-SLN
Patient 1, LN 1 2 3 4 5 6 7
Histology 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2
mRNA tyrosinase 2 2 2 2 1 2 2
Patient 2, LN 1 2 3 4 5 6 7
Histology 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2
mRNA tyrosinase 2 2 2 1 2 2 2
Patient 8, LN 1 2 3 4 5 6 7 8 9 10 11 12
Histology 2 2 2 2 2 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2 2 2 2 2 2
mRNA tyrosinase 2 1 2 2 2 1 1 2 1 # # #
gp100 2 1 1 2 2 * 1 2 1 # # #
Patient 12, LN 1 2 3 4 5 6 7 8
Histology 2 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2 2
mRNA tyrosinase 2 2 1 2 2 2 # 2
gp100 2 2 * 2 2 1 # 1
Patient 20, LN 1 2 3 4 5 6 7
Histology 2 2 1 2 2 2 2
Immunohistology 2 2 1 2 2 2 2
mRNA tyrosinase 2 2 1 2 2 2 2
gp100 2 2 2 2 2 2 2
Patient 21, LN 122 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17219 20 21 22
Histology 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
mRNA tyrosinase 2 # 2 # 2 # 2 2 2 1 2 2 2 2 # 2 2 1 2
gp100 2 # 2 # 2 # 2 1 2 1 (1) 1 2 1 # 2 * 2 *
Patient 22, LN 1 2 3 4 5 6 7 8 9 10
Histology 2 2 2 2 2 2 2 2 2 2
Immunohistology 2 2 2 2 2 2 2 2 2 2
mRNA tyrosinase 2 2 2 2 2 1 2 2 # 1
gp100 2 2 2 2 1 1 1 2 # 1
LN1 5 SLN; #, not tested: negative GAPDH RT2PCR; *, not tested.
To our knowledge, there are no other studies investigating all
LN of a given LN basin step by step morphologically as well as by
tyrosinase RT–PCR. Regarding all methods applied, in 13 of 24
patients (54%) with pT2–pT4 malignant melanoma the SLN
indicated metastatic involvement.
In three cases the SLN as well as one or more non-SLN
were positive only by tyrosinase RT–PCR. Obviously, these LN
contained only small, morphologically undetectable numbers of
melanoma cells. The frequency of SLN and non-SLN, positive
only for tyrosinase RT–PCR, was found to be 13% and 20%,
respectively. Therefore, up to one-fifth of local LN in pT2–pT4
melanomas may harbor micrometastatic melanoma cells, undetect-
able by conventional microscopy. Occasionally, a positive tyrosinase
RT–PCR, however, might be also due to the presence of nodal
nevocytes. Moreover, a clustering of melanoma cells in the part
used for RT–PCR can not be excluded.
Currently it is not clear, whether melanoma cells demonstrated
only by RT–PCR give rise to clinically overt LN metastasis or
systemic disease. In fact, we have observed patients with fatal
outcome following dissection of morphologically negative SLN,
supporting the clinical impact of undetected micrometastasis.
Patients with morphologically positive SLN showed frequent
involvement of non-SLN (eight of 10 cases), seen by morphology
and/or indicated by tyrosinase RT–PCR.
Interestingly, in seven of 24 cases (29%) we found the SLN to
be negative by all techniques applied but the non-SLN were
positive for tyrosinase and/or gp100 transcripts. One of these cases
additionally showed morphologic evidence for melanoma cells. As
discussed, we believe that nevocytes instead of melanoma cells
were only rarely indicated in the non-SLN by the lineage-specific
mRNA. Thus, up to 30% of patients may harbor metastasis despite
the nondetection of melanoma cells in the SLN. The finding of
negative SLN and positive non-SLN in a given LN dissection
specimen should influence surgical treatment protocols in melan-
oma. In this context, the SLN concept (Glass et al, 1995) depending
on a probability of only 1–2% for the so-called ‘‘skip’’ melanoma
metastases (Morton et al, 1992; Thompson et al, 1995) would have
to be questioned. Although the number of melanoma patients
investigated in our study is too small yet for a clinically relevant
conclusion, a further evaluation of the SLN concept is recom-
mended by our findings.
In comparison with light microscopy, the tyrosinase RT–PCR
has the potential to detect considerable lower numbers of tumor
cells. The question remains, which number of melanoma cells
might cause a recurrence or a metastasis by escaping the immune
surveillance. Nevertheless, the estimation of tyrosinase or other
lineage-specific mRNA in LN of melanoma patients can contribute
to a better understanding of the biologic significance of micromet-
astasis.
We thank U. Heiduk and S. Richter for their excellent technical assistance. The
investigations include a substantial part of the M.D. thesis of B. Bellmann.
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